Product
BCD-245
1 clinical trial
1 indication
Indication
NeuroblastomaClinical trial
An Open-Label, Dose-Escalation, Non-comparative Clinical Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-245 (JSC BIOCAD, Russia) Administered Intravenously to Subjects With NeuroblastomaStatus: Recruiting, Estimated PCD: 2023-06-01